CSS
EVGN icon

Cubist Systematic Strategies’s Evogene EVGN Stock Holding History

Cubist Systematic Strategies’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,663
Closed -$57K – 3010
2021
Q2 		$57K Sell
1,663
-1,195
-42% -$46.8K ﹤0.01% 2775
2021
Q1 		$144K Buy
+2,858
New +$177K ﹤0.01% 2570

Other funds holding EVGN

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Cubist Systematic Strategies's EVGN Position: Q3 2021 in Review

Cubist Systematic Strategies sold out of Evogene (EVGN) in Q3 2021, closing a stake of 1,663 shares — an estimated $57K sold.

Cubist Systematic Strategies first reported a position in EVGN in Q1 2021 and held it in 2 quarters. The position peaked at $144K in Q1 2021. 38 funds tracked by Wall St. Rank hold EVGN as of Q3 2021.

  • Cubist Systematic Strategies reported no remaining Evogene position as of Q3 2021 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,663 Evogene shares in Q3 2021, an estimated $57K.
  • Cubist Systematic Strategies first reported a position in Evogene in Q1 2021 and held it in 2 quarters.
  • Cubist Systematic Strategies's Evogene position peaked at $144K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Evogene as of Q3 2021.

Based on Cubist Systematic Strategies's 13F filing for Q3 2021, filed 15 Nov 2021.